Amryt, a biopharmaceutical company focused on rare and orphan diseases, has signed an agreement for distributing its Lojuxta through RCC Pharma in Switzerland.
Image: Amryt
Lojuxta is a treatment for Homozygous Familial Hypercholesterolemia (HoFH), a rare, life-limiting disease, which impairs the body’s ability to remove LDL cholesterol (“bad” cholesterol) from the blood. Starting before birth, the disease progresses rapidly, and typically results in extremely high blood LDL cholesterol levels, which leads to aggressive and premature narrowing and blocking of blood vessels. Left untreated, heart attack or sudden death may occur in childhood or early adulthood.
Amryt said on Monday in its sec filling that it estimates that there are about 15 patients with HoFH in Switzerland. It said it has received requests from clinicians for access to Lojuxta for Swiss patients and this agreement will now enable Amryt to respond more effectively to such requests. The new agreement comes after November’s deal to cover Amryt’s products for the Kingdom of Saudi Arabia.
Amryt acquired exclusive marketing rights for Lojuxta in the European Economic Area, Switzerland, Middle East, North Africa, Turkey and Israel in December 2016.
Dr. Joe Wiley, Chief Executive Officer of Amryt Pharma, said:
“This new distribution agreement with RCC marks another key step as we expand our footprint for Lojuxta across Europe, the Middle East, and North Africa. RCC is a leading Swiss company with particular expertise in rare diseases, and this agreement will help us to bring Lojuxta to patients suffering from HoFH in Switzerland.”
He said the company will further seek for partners across its licensed territories for Lojuxta.